Skip to main content

Acorda - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

Acorda Therapeutics (ISIN: US00484M1062, WKN: A0BK80) Kursdatum: 21.07.2017 Kurs: 20,650 USD
Beschreibung Daten
Symbol ACOR
Marktkapitalisierung 934.598.336,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Biotechnologie
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet
Letztes Bilanz Update 27.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 21.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
33,07 26,44 0,00% -2,56 49,48 -27,17 1,80 1,41

Firmenbeschreibung

 

 

 

 

 

(16) Quarterly Consolidated Financial Data (unaudited)

 

 

 

 

 

 

 

 

(In thousands, except per share amounts)

 

 

 

 

 

 

 

2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31

 

 

 

 

 

 

 

June 30

 

 

 

 

 

 

 

September 30

 

 

 

 

 

 

 

December 31

 

 

 

 

 

 

 

 

 

Total net revenues (1)

 

 

 

 

 

$99,851

 

 

 

 

 

$113,707

 

 

 

 

 

$148,199

 

 

 

 

 

$130,903

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

81,247

 

 

 

 

 

90,840

 

 

 

 

 

123,299

 

 

 

 

 

104,343

 

 

 

 

 

 

 

 

 

Net (loss) income—basic and diluted (2)

 

 

 

 

 

(3,085)

 

 

 

 

 

997

 

 

 

 

 

3,941

 

 

 

 

 

9,205

 

 

 

 

 

 

 

 

 

Net (loss) income per share—basic

 

 

 

 

 

$(0.07)

 

 

 

 

 

$0.02

 

 

 

 

 

$0.09

 

 

 

 

 

$0.22

 

 

 

 

 

 

 

 

 

Net (loss) income per share—diluted

 

 

 

 

 

(0.07)

 

 

 

 

 

0.02

 

 

 

 

 

0.09

 

 

 

 

 

0.21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31

 

 

 

 

 

 

 

June 30

 

 

 

 

 

 

 

September 30

 

 

 

 

 

 

 

December 31

 

 

 

 

 

 

 

 

 

Total net revenues

 

 

 

 

 

$80,518

 

 

 

 

 

$97,129

 

 

 

 

 

$105,961

 

 

 

 

 

$117,872

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

64,831

 

 

 

 

 

78,071

 

 

 

 

 

85,227

 

 

 

 

 

92,737

 

 

 

 

 

 

 

 

 

Net income—basic and diluted (3)

 

 

 

 

 

703

 

 

 

 

 

4,685

 

 

 

 

 

11,953

 

 

 

 

 

331

 

 

 

 

 

 

 

 

 

Net income per share—basic

 

 

 

 

 

$0.02

 

 

 

 

 

$0.11

 

 

 

 

 

$0.29

 

 

 

 

 

$0.01

 

 

 

 

 

 

 

 

 

Net income per share—diluted

 

 

 

 

 

0.02

 

 

 

 

 

0.11

 

 

 

 

 

0.28

 

 

 

 

 

0.01

 

 

 

 

 

 

 

 

 

 

 

 

(1)

 

 

 

In the third quarter of 2015, the Company recognized a one-time increase in net revenue of $22.2 million, representing previously deferred product sales for Zanaflex products due to the Company’s conversion from the deferred revenue recognition model (sell-through) to the traditional revenue recognition model (sell-in).

 

 

 

 

 

(2)

 

 

 

In the third quarter of 2015, the Company made a payment of $8.75 million to the former shareholders of Neuronex in exchange for certain modifications to the Company’s future contingent payment obligations pertaining to Plumiaz.  This payment was reflected as R&D expense.

 

 

 

 

 

(3)

 

 

 

In the fourth quarter of 2014 the Company realized a non-recurring impairment charge of $7.0 million to write-off the IPR&D related to the NP-1998 program.

 

 

 

 

Firmenstrategie

 

 

 

 

 

Principles of Consolidation

 

 

 

 

 

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) and include the results of operations of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

 

 

 

 

RevenueRecognitionPolicyTextBlock

 

 

 

Revenue Recognition

 

Ampyra

 

Ampyra is available only through a network of specialty pharmacy providers that provide the medication to patients by mail; Kaiser Permanente, which distributes Ampyra to patients through a closed network of on-site pharmacies; and ASD Specialty Healthcare, Inc. (an AmerisourceBergen affiliate), which distributes Ampyra to the U.S. Bureau of Prisons, the U.S. Department of Defense, the U.S. Department of Veterans Affairs, or VA, and other federal agencies. Ampyra is not available in retail pharmacies. The Company does not recognize revenue from product sales until there is persuasive evidence of an arrangement, delivery has occurred, the price is fixed and determinable, the buyer is obligated to pay the Company, the obligation to pay is not contingent on resale of the product, the buyer has economic substance apart from the Company, the Company has no obligation to bring about the sale of the product, and the amount of returns can be reasonably estimated and collectability is reasonably assured. The Company recognizes product sales of Ampyra following shipment of product to a network of specialty pharmacy providers, Kaiser Permanente, and ASD Specialty Healthcare, Inc. The specialty pharmacy providers, Kaiser Permanente, and ASD Specialty Healthcare, Inc. are contractually obligated to hold no more than an agreed number of days of inventory, ranging from 10 to 30 days.

 

The Company’s net revenues represent total revenues less allowances for customer credits, including estimated discounts, rebates, and chargebacks. These allowances are recorded for cash consideration given by a vendor to a customer that is presumed to be a reduction of the selling prices of the vendor’s products or services and, therefore, are characterized as a reduction of revenue. At the time product is shipped to specialty pharmacies, Kaiser Permanente and ASD Specialty Healthcare, Inc., an adjustment is recorded for estimated discounts, rebates, and chargebacks. These allowances are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Allowances for discounts, rebates, and chargebacks are established based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products.  Product shipping and handling costs are included in cost of sales. The Company does not accept returns of Ampyra with the exception of product damages that occur during shipping.

 

Zanaflex

 

The Company applies the revenue recognition guidance in Accounting Standards Codification (ASC) 605-15-25, which among other criteria requires that future returns can be reasonably estimated in order to recognize revenue. Prior to the three-month period ended September 30, 2015, the Company accounted for Zanaflex tablet and capsule (Zanaflex products) shipments using a deferred revenue recognition model (sell-through). Under the deferred revenue recognition model, the Company did not recognize revenue upon product shipment.  For product shipments, the Company invoiced the wholesaler, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the wholesaler as a separate component of inventory. The Company recognized revenue when prescribed to the end-user, on a first-in first-out (FIFO) basis. The Company’s revenue to be recognized was based on the estimated prescription demand, based on pharmacy sales for its products using third-party information, including third-party market research data. The Company’s sales and revenue recognition reflected the Company’s estimate of actual product prescribed to the end-user.  Beginning in the third quarter of 2015, the Company is recognizing sales for Zanaflex products when the product is shipped to its wholesale distributors (sell-in), as the Company believes there is now sufficient history to reasonably estimate expected returns.  For the three-month period ended September 30, 2015, the Company recognized a one-time increase in net revenue of $22.2 million, representing previously deferred product sales as of June 30, 2015, net of an allowance for estimated returns.

 

The Company’s net revenues represent total revenues less allowances for customer credits, including estimated discounts, rebates, chargebacks and returns.

 

Qutenza

 

Qutenza is distributed in the U.S. by Besse Medical, Inc., a specialty distributor that furnishes the medication to physician offices; and by ASD Specialty Healthcare, Inc., a specialty distributor that furnishes the medication to hospitals and clinics.  The Company does not recognize revenue from product sales until there is persuasive evidence of an arrangement, delivery has occurred, the price is fixed and determinable, the buyer is obligated to pay the Company, the obligation to pay is not contingent on resale of the product, the buyer has economic substance apart from the Company, the Company has no obligation to bring about the sale of the product, and the amount of returns can be reasonably estimated and collectability is reasonably assured. This means that, for Qutenza, the Company recognizes product sales following shipment of product to its specialty distributors.

 

The Company’s net revenues represent total revenues less allowances for customer credits, including estimated rebates, chargebacks, and returns.

 

Milestones and royalties

 

In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (FASB) guidance on the milestone method of revenue recognition. At the inception of a collaboration agreement the Company evaluates if payments are substantive.  The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonably relative to all deliverable and payment terms of the collaboration arrangement.  If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.

 

 

 

SegmentReportingDisclosureTextBlock

EarningsPerSharePolicyTextBlock

 

 

 

Earnings per Share

 

Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding during the period plus the effect of additional weighted average common equivalent shares outstanding during the period when the effect of adding such shares is dilutive. Common equivalent shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method), the vesting of restricted stock and the potential dilutive effects of the conversion option on the Company’s convertible debt. In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options that are in-the-money. This results in the “assumed” buyback of additional shares, thereby reducing the dilutive impact of stock options.  See Note 8 for discussion on earnings per share.